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est treatment-specific costs. Total costs for the surveillance/compression therapy 
cohort, although lower, were comparable to those that received invasive therapies.
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Objectives: Patients with severe hypertriglyceridemia often experience a variety 
of symptoms, including acute pancreatitis. Little is known about the health care 
cost burden among such patients. This study investigated the real-world health 
care utilization and costs of hypertriglyceridemia in a large commercially insured 
US population. MethOds: A retrospective observational claims study was con-
ducted among adult patients identified from the HealthCore Integrated Research 
DatabaseSM. Patients with TG> 500 mg/dL between 1/1/2007 and 4/30/2013 were 
placed into three mutually exclusive cohorts based on first available TG measure-
ment (index date). Patients were required to have ≥ 12 months of eligibility pre- 
(baseline) and post-index date (follow-up). Baseline and follow-up annual health 
care resource utilization and costs were assessed descriptively using ICD-9-CM 
codes for identification of relevant dyslipidemia claims. Costs associated with an 
acute pancreatitis episode were estimated using GLM. Results: We identified 
N= 1,964 patients with TG≥ 1500 (Cohort A), N= 7,432 with 750≤ TG< 1500 (Cohort 
B), and N= 17,500 with 500< TG< 750 mg/dL (Cohort C). Across all cohorts, patients 
were young (mean age 46-48) and mostly males (75-80%). At baseline, health care 
utilization and costs were similar between Cohorts B and C, but higher in Cohort 
A (mean all-cause medical and pharmacy costs of $8,850/patient). At follow-up, 
the number of patients with dyslipidemia-related office and other outpatient vis-
its, as well as pharmacy dispensing, approximately doubled in all three cohorts, 
as did related costs. Mean all-cause costs/patient in Cohort A at follow-up were 
$12,642, of which $3,730 were dyslipidemia-related. Presence of an acute pancreatitis 
episode was associated with a > 300% increase in total all-cause costs in Cohort 
A. cOnclusiOns: In this sample of commercially insured patients, results sug-
gest that health care utilization and costs scale with the level of TG elevation with 
patients having more severe hypertriglyceridemia requiring more medical interac-
tion and pharmacotherapy. Treating severe hypertriglyceridemia and preventing 
acute pancreatitis may result in substantial cost savings.
PCV47
Cost of illness of Wide Pulse Pressure in JaPan
Lara N.1, Ong S.H.2, Machnicki G.3, Roset M.1
1Barcelona, Spain, 2Basel, Switzerland, 3Buenos Aires, Argentina
Objectives: The study aimed to estimate the health care resources used and 
costs among hypertensive patients with wide pulse pressure (wWPP) and without 
(woWPP) in Japan. MethOds: A retrospective chart review was conducted in 15 
physicians’ offices distributed all over Japan. Two historic cohorts of patients were 
included with hypertension for ›3 years, ›20 years old, and two consecutive readings 
showing wWPP (pulse pressure ≥ 60 mmHg) or woWPP 3 to 5 years before inclu-
sion. Patients were followed-up for three years. Variables retrieved were: sociode-
mographic data and comorbidities, variables related with hypertension, including 
target organ damage, hypertension management and the health care resources used 
for the last 12 months of follow-up. The study was approved by an IRB. Direct health 
care costs were estimated based on unit cost on annual basis from payer perspective. 
A regression model was performed for cost data. Statistical significance was set at 
p< 0.05. Results: Overall 276 patients participated; 150 wWPP vs 126 woWPP, 42.0% 
vs 63.5% males (p= 0.0004), mean (SD) age 69.8 (9.9) vs 58.8 (9.9) years (p< 0.0001). 
Mean (SD) health care resources cost of wWPP was ¥88,829.01 (USD 39,061.60), being 
59.5% related to anti-hypertensive pharmacological treatment and 39.7% to out-
patient visits. Mean (SD) cost of woWPP was ¥75,092.16 (31,899.12). Higher costs 
for wWPP patients were due to higher cost of pharmacological treatment (p= 0.02) 
and higher costs of outpatient visits (p= 0.002). In regression model, diagnosis of 
type-2 diabetes mellitus and target organ damage (cerebral hemorrhage/infarc-
tion, left ventricular hypertrophy, proteinuria) were related to a mean increase of 
total cost of ¥11,271 (p= 0.0114) and ¥22,589 (p= 0.0010), respectively. cOnclusiOns: 
Patients wWPP were more frequently females and older than woWPP, and health 
care resources used were greater, mainly due to higher expenses on treatments and 
outpatient visits. Type-2 diabetes mellitus and target organ damage were associated 
to the cost increase.
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Objectives: Cerebrovascular events (CVE) cause major health problems and sig-
nificant financial burden. Concomitant malnutrition may deteriorate prognosis of 
CVE and increase management costs. The study aims to describe daily practice 
for CVE management in patients with/without malnutrition in terms of diagnosis, 
treatment and follow-up. In this abstract, we calculate direct medical costs related 
to CVE in patients with/without malnutrition from the perspective of the local reim-
bursement authority in Turkey (SSI). MethOds: Acute CVE patients are generally 
referred to tertiary centers in Turkey, therefore neurology specialists experienced 
on CVE management from 8 tertiary-centers filled out a questionnaire including 
questions about diagnosis, treatment and follow-up of CVE. Answers were combined 
and summarized by using mean and standard error(SE). Direct medical costs were 
calculated by using package price and drug price lists of SSI in December 2013. Time 
horizon of analysis was 1 year. Monetary results were converted by using 2.1 USD/
TL exchange rate. Results: Mean(SE) 76.4(7.5)% of patients were hospitalized at 
first admittance (mean(SE) 39.2(7.7)% were to intensive-care unit). Mean(SE) mor-
tality rate of the first admittance was 10.3(2.9)%. The first admittance of patients 
with/without malnutrition cost mean(SE) $3062(513) and $1958(372), respectively. 
During 1-year follow-up period; mean(SE) 93.8(15.4)% and 43.3(3.7)% of patients 
with/without malnutrition were expected to experience at least 1 complication, 
respectively. Routine procedures and complications during 1-year follow-up cost 
mean(SE) $2140(390) and $1660(340) for patients with/without malnutrition, respec-
tively. Overall mean(SE) 1-year cost of patient with/without malnutrition $5201(740) 
and $3618(614) respectively. Of total amounts, oral nutrition supplements (ONS) cost 
mean(SE) $868(335) and $501(281) whereas all others cost mean(SE) $4334(807) and 
$3117(636), respectively. cOnclusiOns: The results of analysis revealed that man-
agement of CVE and its complications have a relatively high burden on the Turkish 
health reimbursement system. Moreover, malnutrition increases overall costs and, 
investment in ONS may decrease overall CVE management cost.
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bAckgROund: The health care cost associated with myocardial infarction (MI) is 
highest the first year after an MI. However health care costs may continue to be high 
post MI for patients with stable CAD and at least one additional atherothrombotic 
risk factor. Objectives: To evaluate long term cardiovascular (CV) related and all 
cause health care costs in patients with stable CAD after MI and at least one addi-
tional atherothrombotic risk factors, resembling patients of the PEGASUS trial (NCT 
01225562). MethOds: Health plan members, ≥ 50 years with no prior stroke, hos-
pitalized with an MI diagnosis (index event) and MI free for 12 months (stable CAD) 
were identified from the HealthCore Integrated Research Environment, between 
01/2007 and 11/2011. Rates of MI and stroke hospitalizations during a 2-year follow-
up were calculated. CV related and all cause health care costs were evaluated per 
patient. Hospitalization rates and health care costs were only evaluated in patients 
< 65 years due to data and population limitations in the database. Results: Of 13 
492 stable CAD patients identified, 5357 met the PEGASUS inclusion criteria with at 
least one additional atherothrombotic risk factor (≥ 1 prior MI, diabetes or chronic 
non end-stage renal disease). The MI and stroke related hospitalization rates for 
patients with stable CAD and fulfilling the PEGASUS criteria at 2 years post index 
event, were 7.7% and 2.5%, respectively. The CV related and all cause health care cost 
per patient year during the follow up period were $15 247 and $26 073 for patients 
with and $7 521 and $13 566 for patients without at least one additional athero-
thrombotic risk factor. cOnclusiOns: The economic burden post MI for patients 
below 65 years with stable CAD and at least one additional atherothrombotic risk 
factor in a US managed care population is substantial several years following an MI.
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Objectives: the costs of treatment of patients with pulmonary embolism (PE), 
which has developed after large surgery and includes the cost of hospital stay, 
treatment, the cost of medicines, non-drug technologies and rehabilitation. In most 
studies, cost estimation is performed using a survey of experts and modeling. The 
objectives of the study were to conduct a cost analysis of patients with PE, which 
has showed after the operations in “real” practice. MethOds: A retrospective 
analysis. When analyzing the costs only direct costs were calculated. Total costs 
were counted by adding costs of medicines, transaction costs, costs of laboratory 
and instrumental methods of research, medical services, medical staff, costs of 
hospital stay. Results: 13 patients after various general surgeries. The average 
age was 73.42±3.26 years. All patients had higher risk of venous thromboembolism. 
Postoperatively, patients received thromboprophylaxis. PE has developed by an aver-
age on 12thday after surgery, and in 69.23% of cases the development of PE resulted 
in death. In 92.3% the source of PE was deep vein thrombosis of the lower limbs. 
The costs of 13 patients with PE were 102 174 USD, the average - 7860 USD for 1 
patient (minimum costs - 230 USD, maximum - 26 799 USD). The highest costs were 
drugs – 33 136 USD (32.43%), services of medical staff – 46 483 USD (45.5%), labora-
tory and instrumental methods of investigation – 40 601 USD (10.8%), hospital stay 
– 5659 USD (9.14%), surgeries – 2811 USD (2.75%). cOnclusiOns: the development 
of pulmonary embolism after surgical intervention is not only clinical, but also an 
economic problem. PE develops in average on 12 days after surgery, in 69.23% ends 
in death. The costs of 1 patients in average is 7860 USD. The highest costs were for 
medicines and staff services due to the high cost and frequency of use.
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Objectives: To measure the impact of medical innovation on the health and health 
care costs of obesity, using statins as a case study. MethOds: Life trajectories and 
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medical costs of elderly Americans are forecasted using the Future Elderly Model 
(FEM) – an established dynamic microsimulation model of health of Americans 
aged over 50. The change in the health and health care costs of obesity due to the 
introduction and widespread use of statins are estimated by introducing a scenario 
in which statins have not been discovered, using well-recognized estimates of the 
health impact of statins. Results: Simulations reveal that the life expectancy of 
50-year-olds with a healthy BMI (18.5-< 25) is 0.92 year longer than it would be in a 
world without statins. Among the obese population, the life expectancy gains due 
to statins are of 1.00 year for type 1 obesity (BMI 30-< 35), 1.05 year for type 2 obesity 
(BMI 35-< 40) and 1.07 year for type 3 obesity (BMI≥ 40). These life expectancy gains 
augment the present value of per capita lifetime health care costs by $15,000 for 
individuals with a healthy BMI, $18,000 for type 1 obesity, $19,100 for type 2 obesity 
and $19,800 for type 3 obesity. About 33% of these costs are shouldered by the 
Medicare program. cOnclusiOns: While the widespread use of statins is beneficial 
for individuals of all weight types, its health impact is highest among the obese 
population. Additional health care costs from statin use are small relative to the 
value of life expectancy gains, and mostly paid for by individuals.
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Objectives: To assess the health care costs and resource utilization of patients 
with high risk vascular disease (HRVD). MethOds: A retrospective cohort study was 
conducted using a large employer-based U.S. administrative claims database. This 
study included patients aged 18 to 64 years who had HRVD (defined as cerebrovas-
cular disease [CVD], coronary artery disease with diabetes [CADD], peripheral artery 
disease [PAD], or history of acute coronary syndrome [ACS] [> = 30days through 365 
days after discharge for ACS]) between 10/01/2008 and 09/30/2009, with minimum 
12-month pre-index and 24-month post-index insurance eligibility. Annual health 
care costs and resource utilization were compared across HRVD patients with 1, 2, 
or 3 affected arterial beds for the first and second year follow-up periods. The com-
parison of mean costs between cohorts was conducted using a generalized linear 
model with log link function and gamma distribution. Results: Of 152,290 patients 
who met the selection criteria, 54.4% were male with mean age 54.5(SD= 7.5). Among 
the identified HRVD patients, during the first/second year, 6.8%/4.3% had ≥ 1 hos-
pitalization event and 27.2%/21.5% had ≥ 1 ER visit. The mean annual number of 
physician office visits was 22/18 for the first and second year respectively. Mean 
total annual health care costs per HRVD patient for the first and second year were 
$19,003/$18,547, of which outpatient costs were $9,698/$8,530, inpatient costs were 
$6,286/$6,220, and pharmacy costs were $3,018/$3,797. HRVD-related costs during 
the first ($8,699) and second year ($7,925) accounted for close to half of the overall 
total health care costs. Mean total annual costs in the first and second year were 
$17,820/$17,501, $28,060/$26,554, and $39,306/$36,513 for patients with 1, 2, and 3 
affected arterial beds (P< 0.001). cOnclusiOns: These results show the high eco-
nomic burden of HRVD and the especially high economic burden associated with 
HRVD patients with multiple affected arterial beds.
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Objectives: To assess the health care costs and resource utilization of elderly 
patients with high risk vascular disease (HRVD). MethOds: A retrospective cohort 
study was conducted using the Truven MarketScan Medicare claims database to 
identify patients > = 65 years, who had HRVD (defined as cerebrovascular disease 
[CVD], coronary artery disease with diabetes [CADD], peripheral artery disease [PAD], 
or history of acute coronary syndrome [ACS] [> = 30days through 365 days after 
discharge for ACS]) between 10/01/2008 and 09/30/2009, with minimum 12-month 
pre-index and 24-month post-index insurance eligibility. Annual health care costs 
and resource utilization were compared across HRVD patients with 1, 2, or 3 affected 
arterial beds for the first- and second-year follow-up periods. The comparison of 
mean costs between cohorts was conducted using a generalized linear model with 
log link function and gamma distribution. Results: The cohort included 203,949 
patients with a mean age of 77.0 years; 52.8% were male. Among the identified HRVD 
patients during the first/second year, 7.3%/6.3% had ≥ 1 hospitalization event and 
27.0%/23.2% had ≥ 1 ER visit. The mean annual number of physician office visits 
was 26/20 for the first and second year respectively. Mean total annual health care 
costs per HRVD patient for the first and second year were $17,899/$17,552, of which 
outpatient costs were $8,911/$6,861, inpatient costs were $5,296/$6,167, and phar-
macy costs were $3,692/$4,525. HRVD-related costs during the first ($7,528) and 
second year ($7,565) accounted for more than 40% of the overall total health care 
costs. Mean total annual costs in the first and second year were $16,794/$16,631, 
$22,116/$21,096, and $26,575/$24,556 for patients with 1, 2, and 3 affected arte-
rial beds (P< 0.001). cOnclusiOns: These results show the high economic burden 
of HRVD and the especially high economic burden associated with elderly HRVD 
patients with multiple affected arterial beds.
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Objectives: To evaluate the economic burden and health care utilization of general 
cardiovascular disease (CVD) patients in the U.S. Medicare population. MethOds: 
A retrospective database analysis was conducted using Medicare data (2008-2010). 
General CVD patients were identified using myocardial infarction (International 
Classification of Disease, 9th Revision, Clinical Modification [ICD-9-CM] codes 410.
xx, 412.xx), unstable angina (411.1x, 411.81, 411.89), ischemic stroke (434.xx, 436.
xx, 437.0x, 437.1x, 438.xx, 997.02), transient ischemic attack (435.xx), heart failure 
(428.xx) and percutaneous coronary intervention (ICD-9 procedure codes 00.66, 
36.09). The first diagnosis date was designated as the index date. One-year con-
tinuous enrollment pre- and post-index date was required. Charlson Comorbidity 
Index (CCI) score and comorbid conditions were examined for the baseline period. 
Prescribed medications were evaluated within 60 days post-diagnosis. Health care 
utilization and costs were measured for the follow-up period. Results: A total 
of 203,865 patients were identified for study (mean age 78.9 years). CVD patients 
were more often female (60.7%), Caucasian (86.0%) and resided in the Southern U.S. 
region. (39.5%). The baseline CCI score was 1.86, and the most frequently diagnosed 
comorbid conditions were diabetes (32.8%), tumor (31.0%) and chronic obstructive 
pulmonary disease (25.6%). Furosemide (13.6%) was most often prescribed within 60 
days after diagnosis, followed by simvastatin (11.4%) and lisinopril (10.6%). Health 
care utilization including Medicare carrier (98.3%), Durable Medical Equipment 
(DME, 43.9%), Home Health Agency (HHA, 25.6%), outpatient visits (80.5%) and inpa-
tient hospital (52.8%), Skilled Nursing Facility (SNF, 17.7%) and hospice admissions 
(8.4%) and prescription claims (54.4%) were observed for the follow-up period. CVD 
patients incurred higher Medicare carrier ($5,679), DME ($534), HHA ($1,506), outpa-
tient ($16,455), inpatient ($12,230), SNF ($3,489), hospice ($822), pharmacy ($1,818) 
and total costs ($42,533). cOnclusiOns: General CVD Medicare patients utilized 
a high percentage of Medicare carrier, outpatient and inpatient utilizations, and 
incurred high health care expenses.
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Objectives: Cardiovascular (CV) disease significantly contributes to morbidity and 
mortality in chronic obstructive pulmonary disease (COPD) patients; however, the 
economic burden of acute CV events in this population is still unknown. Our objec-
tive was to estimate the direct medical costs associated with the development of 
acute CV events in patients with COPD. MethOds: We identified patients with a 
COPD diagnosis (ICD-9 491.x, 492.x, 496.x) between 2005-2010 in the IMS LifeLink 
Health Claims Database. Patients experiencing an incident CV event (MI, ACS, CHF, 
arrhythmia, or stroke) resulting in an ER visit or inpatient admission (case index) 
were matched to up to 3 controls on age, region, gender, year of COPD diagnosis, 
and time between COPD diagnosis and index date. Mean costs (total, inpatient, 
outpatient, and pharmacy) in the 12 months before and after the case index and 
control index were compared, with total costs attributable to the incident CV event 
determined by using a difference in differences regression to adjust for patient 
comorbidities. Results: Among 9,537 case and 26,128 control patients, the aver-
age age was 69.1 years and 51% were male. Hypertension, diabetes, and coronary 
atherosclerosis were the most prevalent comorbidities. Total costs were $27,300 and 
$15,016 (pre-index), and $51,468 and $15,596 (post-index) for cases and controls, 
respectively. Regression analysis resulted in an adjusted difference in differences 
value of $23,601 (p< 0.001). As a percentage of total costs, pharmacy and outpatient 
costs decreased between the pre-index and post-index periods (13% to 8% and 
28% to 22%), while inpatient costs increased (59% to 69%); percentages for control 
patients remained unchanged. cOnclusiOns: The development of acute CV events 
in COPD patients is associated with a large increase in direct medical costs, pre-
dominantly driven by inpatient costs. Interventions aimed at reducing the incidence 
of acute CV events in this population are needed to mitigate overall cost burden.
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Objectives: This study evaluated the hospital resource utilization associated with 
major adverse cardiovascular events (MACE) in the United States (US) from 2000 to 
2010, overall and by type of event. Of special interest was the rate of death during 
MACE-related hospitalizations. MethOds: The Healthcare Cost and Utilization 
Project (HCUP) Nationwide Inpatient Sample (NIS) database was used to estimate 
the annual rates of MACE-related hospitalization for adults aged at least 18 years 
per 100,000 adults as well as per 100,000 adult hospitalizations in the US from 
2000 to 2010 using NIS sampling weights and yearly US Census population infor-
mation. Additionally, average MACE-related per-hospitalization costs (standard-
ized to 2013 USD) and length of stay (LOS) estimates were calculated for each year. 
MACE-related hospitalizations were identified as those with a primary discharge 
diagnosis of acute myocardial infarction (AMI), stroke, or cardiac arrest. Results: 
Rates of MACE-related hospitalization have steadily decreased over time from 685 
to 525 per 100,000 adults and from 4,650 to 3,611 per 100,000 hospitalizations among 
adults in the US from 2000 to 2010. The percentage of MACE-related hospitaliza-
tions resulting in death also decreased from 7.5% in 2000 to 5.3% in 2010. During 
this period, the AMI-related stays accounted for the largest percentage of MACE-
related hospitalizations (51.2%-55.5%), followed by stroke-related (43.9%-48.2%), 
and cardiac arrest-related (0.5%-0.7%) stays. The mean (standard deviation [SD]) 
LOS for MACE-related hospitalizations decreased from 5.4 (6.7) days in 2000 to 4.7 
(5.5) days in 2010. However, the mean (SD) costs per MACE-related hospitalization 
increased from $18,389 ($25,244) in 2000 to $28,629 ($35,008) in 2010. cOnclusiOns: 
Hospitalization and inpatient fatality rates, as well as LOS per hospitalization associ-
ated with MACE have decreased, while costs per MACE-related hospitalization have 
risen in the US between 2000 and 2010. Further research may elucidate the drivers 
of these directionally opposing trends.
